{"id":"W4394780042","doi":"10.1093/ecco-jcc/jjae038","title":"Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical Programme","year":2024,"lang":"en","type":"article","venue":"Journal of Crohn s and Colitis","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":37,"is_retracted":false,"has_abstract":true,"ca_institutions":"Pfizer (Canada); Western University; McGill University Health Centre","funders":"Allergan; Genentech; KU Leuven; Pfizer Canada; Universiteit van Amsterdam; Silverback Therapeutics; Celltrion; Teva Pharmaceutical Industries; Gilead Sciences; Mylan; Celgene; Biogen; GlaxoSmithKline; Amgen; Dr. Falk Pharma; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Proctitis; Ulcerative colitis; Placebo; Internal medicine; Gastroenterology; Clinical endpoint; Post-hoc analysis; Clinical trial; Colitis; Inflammatory bowel disease; Phases of clinical research; Disease; Pathology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005199991,0.0007806568,0.002086168,0.0003100641,0.0002797521,0.0006338158,0.0004116018,0.0006544312,0.002909784],"category_scores_gemma":[0.003182531,0.0002719386,0.002268597,0.0003992251,0.0006016811,0.0005497016,0.0004719355,0.001498671,0.0003813932],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003361366,"about_ca_system_score_gemma":0.0007245274,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002612845,"about_ca_topic_score_gemma":0.000746296,"domain_scores_codex":[0.9984149,0.001107938,0.0001176251,0.000123444,0.000129408,0.0001067583],"domain_scores_gemma":[0.9963776,0.001516205,0.001008302,0.0002879393,0.00024933,0.0005606532],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9087877,0.005995295,0.01073867,0.0009899727,0.00262249,0.0001094156,0.00011196,0.0006780502,0.009364059,0.00005075623,0.001244396,0.05930733],"study_design_scores_gemma":[0.4927381,0.3973156,0.09911914,0.0001491143,0.003512139,0.0005499913,0.00009651336,0.0007996337,0.002844125,0.0001553148,0.002661124,0.00005921094],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9882061,0.008167887,0.000376092,0.000323529,0.00004835741,0.0006120375,0.0008987833,0.00003646726,0.001330862],"genre_scores_gemma":[0.9946519,0.001926599,0.0006120568,0.0004081978,0.0001558235,0.0003882105,0.001272304,0.00001298339,0.0005719029],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005199991,"threshold_uncertainty_score":0.02750045,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01222658706844179,"score_gpt":0.2854720386708682,"score_spread":0.2732454516024265,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}